Trial: 201801118

A phase I/II dose-escalation study evaluating the safety and efficacy of 21 Gy, 23 Gy, and 25 Gy for high dose rate (HDR) prostate brachytherapy

Phase

I/II

Principal Investigator

Gay, Hiram

Disease Site

Prostate

Learn more about this study at: clinicaltrials.gov